🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

REtroperitoneal SArcoma Registry: an International Prospective Initiative

Recruitingn/aAges 18 Years - anyAllFondazione IRCCS Istituto Nazionale dei Tumori, M…
NCT03838718 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Surgery is currently the only potentially curative treatment modality for localized retroperitoneal sarcoma (RPS). Available studies regarding oncologic outcomes are mainly retrospective in nature, and RPS are recognized as a rare disease. Therefore, prospective analysis of high quality data is a top priority. Primary Objectives of this study are: * to prospectively collect standardized clinical data and radiological and pathological material from primary RPS patients treated with surgery at reference centers. * patient outcome will be evaluated in terms of overall survival (OS), disease-free survival (DFS), crude cumulative incidence (CCI) of local recurrence (LR) and distant metastasis (DM). Secondary Objectives: * to estimate the efficacy and safety of surgical treatment, including extended surgical approach to primary RPS; * to prospectively evaluate the impact of multimodality t

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * primary RPS operated on in the participating center; * age\>18 years at the time of the first treatment (pediatric patients can not be included) * histological confirmed diagnosis according to the WHO criteria done on biopsy or surgical specimen by dedicated sarcoma pathologist; * radiological examinations performed (contrast enhanced abdominal CT scan and/or MRI) prior to surgical resection; * signed informed consent form; * adequate compliance of the patients to the plan of follow-up Exclusion Criteria: * age\<18 years; * recurrent tumor; * benign retroperitoneal tumors; * serious psychiatric disease that precludes informed consent or limits compliance; * impossibility to ensure adequate follow-up
💊

What it tests

  • Not listed
📍

Where

22 sites
University of Southern California (USC)
Los Angeles, United States
Mayo Clinic
Jacksonville, United States
Moffitt Cancer Center
Tampa, United States
Winship Cancer Institute
Emory, United States
Brigham and Women's Hospital/Dana-Farber Cancer Institute
Boston, United States
The Ohio State University
Columbus, United States
Peter MacCallum Cancer Center
Melbourne, Australia
Maisonneuve-Rosemont Hospital / University of Montreal
Montreal, Canada

…and 14 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy